DK3378859T3 - Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin - Google Patents
Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin Download PDFInfo
- Publication number
- DK3378859T3 DK3378859T3 DK16865671.8T DK16865671T DK3378859T3 DK 3378859 T3 DK3378859 T3 DK 3378859T3 DK 16865671 T DK16865671 T DK 16865671T DK 3378859 T3 DK3378859 T3 DK 3378859T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzofurand
- medicine
- derivatives
- preparing
- benzofurand derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510800975 | 2015-11-19 | ||
| PCT/CN2016/104318 WO2017084494A1 (zh) | 2015-11-19 | 2016-11-02 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3378859T3 true DK3378859T3 (da) | 2020-01-20 |
Family
ID=58717310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16865671.8T DK3378859T3 (da) | 2015-11-19 | 2016-11-02 | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10759787B2 (es) |
| EP (1) | EP3378859B1 (es) |
| JP (1) | JP6828229B2 (es) |
| KR (1) | KR20180081587A (es) |
| CN (1) | CN107428742B (es) |
| AU (1) | AU2016357900B2 (es) |
| BR (1) | BR112018007876B1 (es) |
| CA (1) | CA3002436A1 (es) |
| DK (1) | DK3378859T3 (es) |
| ES (1) | ES2760510T3 (es) |
| HK (1) | HK1243414A1 (es) |
| HR (1) | HRP20192209T1 (es) |
| HU (1) | HUE047785T2 (es) |
| LT (1) | LT3378859T (es) |
| MX (1) | MX2018005019A (es) |
| PL (1) | PL3378859T3 (es) |
| PT (1) | PT3378859T (es) |
| RS (1) | RS59763B1 (es) |
| RU (1) | RU2727198C2 (es) |
| SI (1) | SI3378859T1 (es) |
| TW (1) | TWI718207B (es) |
| WO (1) | WO2017084494A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| EP3626239A4 (en) * | 2017-05-18 | 2021-03-10 | Jiangsu Hengrui Medicine Co., Ltd. | USE OF AN EZH2 INHIBITOR COMBINED WITH A BTK INHIBITOR IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMOR |
| CN109937200B (zh) * | 2017-05-18 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
| CN111094279B (zh) * | 2017-11-10 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃衍生物的制备方法 |
| ES2923290T3 (es) | 2018-01-31 | 2022-09-26 | Mirati Therapeutics Inc | Inhibidores de PRC2 |
| CN110179796B (zh) * | 2018-02-23 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物的组合物及制备方法 |
| CA3098428A1 (en) * | 2018-04-18 | 2019-10-24 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
| CN112512580B (zh) * | 2018-09-29 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 |
| JP7395807B2 (ja) | 2019-03-25 | 2023-12-12 | 上海華匯拓医薬科技有限公司 | アミド類化合物の調製方法及びその医薬分野の使用 |
| WO2020220562A1 (zh) * | 2019-04-29 | 2020-11-05 | 上海和誉生物医药科技有限公司 | 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 |
| WO2020228591A1 (zh) * | 2019-05-10 | 2020-11-19 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
| CN110003187B (zh) * | 2019-05-10 | 2021-11-05 | 南京工业大学 | 一种多氟烷基取代苯并呋喃类化合物及其制备方法 |
| CN112007162B (zh) * | 2019-05-30 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 |
| CN110172448B (zh) * | 2019-05-30 | 2020-07-28 | 中南大学湘雅二医院 | 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系 |
| CN114040776B (zh) * | 2019-06-28 | 2024-05-14 | 江苏恒瑞医药股份有限公司 | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 |
| TW202114663A (zh) * | 2019-09-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | EZH2抑制劑與含有TGF-β受體的融合蛋白聯合在製備治療腫瘤的藥物中的用途 |
| WO2021063332A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 |
| TW202126302A (zh) * | 2019-09-30 | 2021-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｚｈ２抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| KR20240056564A (ko) | 2021-08-30 | 2024-04-30 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도 |
| CA3234851A1 (en) | 2021-10-15 | 2023-04-20 | Ya CHEN | Method for preparing benzofuran derivative |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110275630A1 (en) | 2003-06-02 | 2011-11-10 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| KR20100117073A (ko) * | 2008-02-14 | 2010-11-02 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| PT2566327T (pt) * | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| EP2410171A1 (en) | 2010-07-23 | 2012-01-25 | Ewt Ip B.V. | Wind turbine having a rotor with hub |
| SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
| AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| WO2013039988A1 (en) * | 2011-09-13 | 2013-03-21 | Glax0Smithkline Llc | Azaindazoles |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CA2910873A1 (en) | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| PL3121175T3 (pl) | 2014-03-17 | 2020-06-01 | Daiichi Sankyo Company, Limited | Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2 |
-
2016
- 2016-11-02 KR KR1020187016692A patent/KR20180081587A/ko not_active Application Discontinuation
- 2016-11-02 HU HUE16865671A patent/HUE047785T2/hu unknown
- 2016-11-02 WO PCT/CN2016/104318 patent/WO2017084494A1/zh active Application Filing
- 2016-11-02 US US15/775,958 patent/US10759787B2/en active Active
- 2016-11-02 LT LTEP16865671.8T patent/LT3378859T/lt unknown
- 2016-11-02 AU AU2016357900A patent/AU2016357900B2/en active Active
- 2016-11-02 BR BR112018007876-0A patent/BR112018007876B1/pt active IP Right Grant
- 2016-11-02 EP EP16865671.8A patent/EP3378859B1/en active Active
- 2016-11-02 RU RU2018119173A patent/RU2727198C2/ru active
- 2016-11-02 MX MX2018005019A patent/MX2018005019A/es unknown
- 2016-11-02 JP JP2018523005A patent/JP6828229B2/ja active Active
- 2016-11-02 CA CA3002436A patent/CA3002436A1/en active Pending
- 2016-11-02 CN CN201680013259.7A patent/CN107428742B/zh active Active
- 2016-11-02 DK DK16865671.8T patent/DK3378859T3/da active
- 2016-11-02 RS RS20191628A patent/RS59763B1/sr unknown
- 2016-11-02 PT PT168656718T patent/PT3378859T/pt unknown
- 2016-11-02 SI SI201630514T patent/SI3378859T1/sl unknown
- 2016-11-02 PL PL16865671T patent/PL3378859T3/pl unknown
- 2016-11-02 ES ES16865671T patent/ES2760510T3/es active Active
- 2016-11-16 TW TW105137422A patent/TWI718207B/zh active
-
2018
- 2018-03-01 HK HK18102969.3A patent/HK1243414A1/zh unknown
-
2019
- 2019-12-09 HR HRP20192209TT patent/HRP20192209T1/hr unknown
-
2020
- 2020-07-22 US US16/935,407 patent/US11059811B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3378859T3 (da) | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin | |
| DK3354649T3 (da) | Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler | |
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3505519T3 (da) | Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin | |
| DK3643709T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3153169T3 (da) | Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt | |
| DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3250237T3 (da) | Hemiasterlinderivater til konjugering og terapi | |
| DK3265043T3 (da) | Hjælpemiddel til patienttransport og -træning | |
| DK3559000T3 (da) | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf | |
| DK3310805T3 (da) | Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3305310T3 (da) | Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf | |
| DK3094640T3 (da) | Fremgangsmåder til steril kromatografi og fremstilling | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3357343T3 (da) | Fedtsammensætning og fremgangsmåde til fremstilling heraf | |
| DK3220973T3 (da) | Kunstigt lungesystem og fremgangsmåder til anvendelse deraf | |
| DK3185872T3 (da) | Formulering af testosteron og metoder til behandling hermed | |
| DK3183201T3 (da) | Spilsamling og fremgangsmåde til anvendelse | |
| DK3495482T3 (da) | Fremgangsmåde til fremstilling af dna-enhedssammensætning og fremgangsmåde til frembringelse af concatenat-dna | |
| DK3353191T3 (da) | Cykliske polypeptider, fremgangsmåde til opnåelse deraf og terapeutisk anvendelse deraf | |
| DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
| DK3057589T3 (da) | (s)-pirlindol og farmaceutisk acceptable salte heraf til anvendelse i medicin |